Sangamo Therapeutics (LTS:0R1D) Beginning Cash Position : $46.70 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sangamo Therapeutics Beginning Cash Position?

Sangamo Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was $46.70 Mil.

Sangamo Therapeutics's quarterly Beginning Cash Position declined from Sep. 2023 ($68.33 Mil) to Dec. 2023 ($58.01 Mil) and declined from Dec. 2023 ($58.01 Mil) to Mar. 2024 ($46.70 Mil).

Sangamo Therapeutics's annual Beginning Cash Position increased from Dec. 2021 ($132.83 Mil) to Dec. 2022 ($180.37 Mil) but then declined from Dec. 2022 ($180.37 Mil) to Dec. 2023 ($101.94 Mil).

Sangamo Therapeutics Beginning Cash Position Historical Data

The historical data trend for Sangamo Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Beginning Cash Position Chart

Sangamo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

143.92

81.93

132.83

180.37

101.94

Sangamo Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															101.94	79.74	68.33	58.01	46.70

Sangamo Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Sangamo Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangamo Therapeutics (LTS:0R1D) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (LTS:0R1D) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

SGMO:USA GBY:Germany

Address

7000 Marina Boulevard, Brisbane, CA, USA, 94005

Website

https://www.sangamo.com

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Sangamo Therapeutics (LTS:0R1D) Headlines

No Headlines